


AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A compound of the formula I,



wherein


R⁰ is 1) a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by R₈,
2) a monocyclic or bicyclic 4- to 15-membered heterocyclyl selected from the group consisting of benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, iso chromanyl, isoindolyl, isoquinoliny, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl and 4,4,5,6-tetrahydro-pyridazinyl, wherein said heterocyclyl which is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈, or
3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, isoxazolyl, which wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈, and is additionally substituted by a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, thienyl, wherein the heterocyclylthienyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R₈;

R₈ is 1) halogen,
2) -NO₂,
3) -CN,
4) -C(O)-NH₂,
5) -OH,
6) -NH₂,
7) -O-CF₃

- 8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by halogen or \sim O-(C₁-C₈)-alkyl,
- 9) -(C₁-C₈)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or methoxy,
- 10) \sim O-(C₁-C₈)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or methoxy,
- 11) \sim SO₂-CH₃ or
- 12) \sim SO₂-CF₃,

provided that when R⁹ is a monocyclic or bicyclic 6- to 14-membered aryl, then R₈ is at least one of the substituent of the aryl is halogen, -C(O)-NH₂ or \sim O-(C₁-C₈)-alkyl;

the substructure



in formula I is a 4- to 8-membered saturated, partially unsaturated or aromatic cyclic group containing zero, 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen pyridyl, and is unsubstituted or substituted 1, 2, 3, 4, 5 or 6 times by R₃, or substituted 1 or 2 times by =O; provided that said cyclic group is not a phenyl residue;

Q is a direct bond, -(C₀-C₂)-alkylene-C(O)-NR¹⁰-, -NR¹⁰-C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -(C₁-C₆)-alkylene, -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n-, -(CH₂)_m-S-(CH₂)_n-, -(CH₂)_m-C(O)-(CH₂)_n-, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n-, -(CH₂)_m-NR¹⁰-SO₂-NR¹⁰-(CH₂)_n-, -(CH₂)_m-CH(OH)-(CH₂)_n-, -(CH₂)_m-O-C(O)-NR¹⁰-(CH₂)_n-, -(C₂-C₃)-alkylene-O-(C₀-C₃)-alkylene-, -(C₂-C₃)-alkylene-S(O)-, -(C₂-C₃)-alkylene-S(O)₂-, -(CH₂)_m-NR¹⁰-C(O)-O-(CH₂)_n-, -(C₂-C₃)-alkylene-S(O)₂-NH-(R¹⁰)-, -(C₂-C₃)-alkylene-N(R¹⁰)- or -(C₀-C₃)-alkylene-C(O)-O-(CH₂)_m-, wherein -(CH₂)_m- or -(CH₂)_n- are alkylene that is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH, or -(C₃-C₆)-cycloalkylene, thatwhich is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH;

R¹ is hydrogen, -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or substituted one to three times by R13, -(C₁-C₃)-alkylene-C(O)-NH- R⁰, -(C₁-C₃)-alkylene-C(O)-O-R¹⁵, a monocyclic or bicyclic 6- to 14-membered aryl, wherein the aryl is mono-, di- or trisubstituted independently of one another by R8; a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen, -(C₁-C₃)-perfluoroalkylene, -(C₁-C₃)-alkylene-S(O)-(C₁-C₄)-alkyl, -(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl, -(C₁-C₃)-alkylene-S(O)₂-N(R⁴)-R⁵, -(C₁-C₃)-alkylene-O-(C₁-C₄)-alkyl, or -(C₀-C₃)-alkylene-(C₃-C₈)-cycloalkyl, or -(C₀-C₃)-alkylene-het, wherein the het is a 3- to 7-membered cyclic residue, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, and is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R⁴ and R⁵ are independent of one another are identical or different and are hydrogen atom or -(C₁-C₄)-alkyl;

R² is a direct bond or -(C₁-C₄)-alkylene, or

R⁴ and R³ together with the atoms to which they are bonded form a 6- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R⁴-N(R³)-V form a 4- to 7-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, and wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R14 is halogen, -OH, =O, -(C₁-C₈)-alkyl, -(C₁-C₄)-alkoxy, -NO₂, -C(O)-OH, -CN, -NH₂, -C(O)-O-(C₁-C₄)-alkyl, -(C₀-C₈)-alkyl-SO₂-(C₁-C₄)-alkyl, -(C₀-C₈)-alkyl-SO₂-(C₁-C₃)-perfluoroalkyl, -(C₀-C₈)-alkyl-SO₂-N(R¹⁸)-R²¹, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N-[(C₁-C₈)-alkyl]₂, -NR¹⁸-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂, -S-R¹⁸, or -NR¹⁸-C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R¹⁸ and R²¹ are independently from each other hydrogen, -(C₁-C₃)-perfluoroalkyl or -(C₁-C₆)-alkyl;

V is

- 4) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein the cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;
- 2) a 6- to 14-membered aryl, wherein the aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
- 3) a monocyclic or bicyclic 4- to 15-membered heterocyclic piperidinyl, pyridyl, imidazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, tetrazolyl, or thiazolyl, each of which wherein the heterocyclic is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

G is a direct bond, $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-CH(OH)-(CH_2)_n-$, $-(CH_2)_m-$,
 $-(CH_2)_m-O-(CH_2)_n-$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n-$, $-(CH_2)-SO_2-(CH_2)_n-$,
 $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n-$,
 $-(CH_2)_m-C(O)-(CH_2)_n-$, $-(CH_2)-S-(CH_2)_n-$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n-$,
 $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n-$, $-(CH_2)_m-NR^{10}-$, $-(CH_2)_m-O-C(O)-NR^{10}-(CH_2)_n-$ or
 $-(CH_2)_m-NR^{10}-C(O)-O-(CH_2)_n-$;

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6;

M is


- 1) hydrogen,
- 2) $-(C_1-C_8)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
- 3) $-C(O)-N(R11)-R12$,
- 4) $-(CH_2)_m-NR^{10}$,
- 5) a 6- to 14-membered aryl, wherein the aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
- 6) a monocyclic or bicyclic 4- to 15-membered heterocyclic piperidinyl, pyridyl, imidazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, tetrazolyl, or thiazolyl, each of which wherein the heterocyclic is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
- 7) $-(C_3-C_8)$ -cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

8) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R3 is



- 1) hydrogen,
- 2) halogen,
- 3) -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 4) -(C₁-C₃)-perfluoroalkyl,
- 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 6) -(C₀-C₄)-alkylene-O-R19,
- 7) -NO₂,
- 8) -CN,
- 9) -SO_s-R¹¹, wherein s is 1 or 2,
- 10) -SO_t-N(R¹¹)-R¹², wherein t is 1 or 2,
- 11) -(C₀-C₄)-alkylene-C(O)-R¹¹,
- 12) -(C₀-C₄)-alkylene-C(O)-O-R¹¹,
- 13) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-R¹²,
- 14) -(C₀-C₄)-alkylene-N(R¹¹)-R¹²,
- 15) -NR¹⁰-SO₂-R¹⁰,
- 16) -S-R¹⁰,
- 17) -(C₀-C₂)alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-(C₁-C₄)-alkyl,
- 18) -C(O)-O-C(R15, R16)-O-C(O)-R17,
- 19) -(C₀-C₂)alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-O-(C₁-C₆)-alkyl,
- 20) -C(O)-O-C(R15, R16)-O-C(O)-O-R17,
- 21) -(C₀-C₄)-alkylene-(C₆-C₁₄)-aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R13,
- 22) -(C₀-C₄)-alkylene-(C₄-C₁₅)-heterocyclyl, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13
- 23) -(C₀-C₄)-alkylene-(C₃-C₈)-cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 24) -(C₀-C₄)-alkylene-het, wherein the het is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

- 25) $-(C_0-C_4)\text{-alkylene-O-CH}_2\text{-}(C_1-C_3)\text{-perfluoroalkylene-CH}_2\text{-O-}(C_0-C_4)\text{-alkyl}$,
- 26) $-\text{SO}_w\text{-N(R}^{11}\text{)-R}^{13}$, wherein w is 1 or 2,
- 27) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-R}^{13}$,
- 28) $-(C_0-C_4)\text{-alkylene-N(R}^{11}\text{)-R}^{13}$, or
- 29) a residue selected from the group consisting of



wherein Me is methyl;

R19 is a) hydrogen,
 b) $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by $R13$ halogen, $-NO_2$, $-CN$, $=O$, $-OH$, $-CF_3$, $-C(O)-O-R^{10}$, $-C(O)-N(R^{10})-R^{20}$, $-N(R^{10})-R^{20}$, $-(C_0-C_3)$ -alkylene- $O-R^{10}$, $-Si-(CH_3)_3$, $-N(R^{10})-S(O)_{R^u}R^{10}$, wherein u is 1 or 2, $-S-R^{10}$, $-SO_r-R^{10}$, wherein r is 1 or 2, $-S(O)_v-N(R^{10})-R^{20}$, wherein v is 1 or 2, $-C(O)-R^{10}$, $-(C_1-C_8)$ -alkyl, $-(C_1-C_8)$ -alkoxy, phenoxy-, $-O-CF_3$, $-(C_0-C_4)$ -alkyl- $C(O)-O-C(R15, R16)-O-C(O)-R17$, $-(C_1-C_4)$ -alkoxy-phenyl, $-(C_0-C_4)$ -alkyl- $C(O)-O-C(R15, R16)-O-C(O)-O-R17$, $-(C_1-C_3)$ -perfluoroalkyl, $-O-R15$, $-NH-C(O)-NH-R^{10}$, $-NH-C(O)-O-R^{10}$ or a residue selected from the group consisting of



, wherein Me is methyl,

- c) $-\text{CF}_3$, or
- d) $-\text{CHF}_2$,

or two $-\text{OR}^{19}$ residues and adjacent atoms through which they are attached may form together a 5- or 6-membered ring, that is unsubstituted or substituted one, two, three or four times by R13;


R11 and R12 are independently of one another identical or different and are

- 1) hydrogen,
- 2) $-(\text{C}_1\text{-C}_6)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(\text{C}_0\text{-C}_6)$ -alkyl- $(\text{C}_3\text{-C}_8)$ -cycloalkyl,
- 4) $-\text{SO}_t\text{-R}^{10}$, wherein t is 1 or 2,
- 5) $-(\text{C}_0\text{-C}_6)$ -alkyl- $(\text{C}_6\text{-C}_{14})$ -aryl, wherein the alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13,
- 6) $-(\text{C}_1\text{-C}_3)$ -perfluoroalkyl, or
- 7) $-\text{O-R}^{17}$, or
- 8) $-(\text{C}_0\text{-C}_6)$ -alkyl- $(\text{C}_4\text{-C}_{15})$ -heterocyclyl, wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded form a 4- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

R13 is halogen, $-\text{NO}_2$, $-\text{CN}$, $=\text{O}$, $-\text{OH}$, $-\text{CF}_3$, $-\text{C}(\text{O})\text{-O-R}^{10}$, $-\text{C}(\text{O})\text{-N}(\text{R}^{10})\text{-R}^{20}$, $-\text{N}(\text{R}^{10})\text{-R}^{20}$, $-(\text{C}_3\text{-C}_8)$ -cycloalkyl, $-(\text{C}_0\text{-C}_3)$ -alkylene- O-R^{10} , $-\text{Si}(\text{CH}_3)_3$, $-\text{N}(\text{R}^{10})\text{-S}(\text{O})_u\text{-R}^{10}$, wherein u is 1 or 2, $-\text{S-R}^{10}$, $-\text{SO}_r\text{-R}^{10}$, wherein r is 1 or 2, $-\text{S}(\text{O})_v$ -

$\text{N}(\text{R}^{10})\text{-R}^{20}$, wherein v is 1 or 2, $-\text{C}(\text{O})\text{-R}^{10}$, $-(\text{C}_1\text{-C}_8)\text{-alkyl}$, $-(\text{C}_1\text{-C}_8)\text{-alkoxy}$, phenyl, phenyloxy-, $-\text{O-}\text{CF}_3$, $-(\text{C}_0\text{-C}_4)\text{-alkyl-}\text{C}(\text{O})\text{-O-}\text{C}(\text{R}15, \text{R}16)\text{-O-}\text{C}(\text{O})\text{-R}17$, $-(\text{C}_1\text{-C}_4)\text{-alkoxy-phenyl}$, $-(\text{C}_0\text{-C}_4)\text{-alkyl-}\text{C}(\text{O})\text{-O-}\text{C}(\text{R}15, \text{R}16)\text{-O-}\text{C}(\text{O})\text{-O-}\text{R}17$, $-(\text{C}_1\text{-C}_3)\text{-perfluoroalkyl}$, $-\text{O-}\text{R}15$, $-\text{NH-}\text{C}(\text{O})\text{-NH-}\text{R}^{10}$, $-\text{NH-}\text{C}(\text{O})\text{-O-}\text{R}^{10}$ or a residue selected from the group consisting of



R^{10} and R^{20} are independently of one another hydrogen, $-(C_1-C_6)$ -alkyl, $-(C_0-C_4)$ -alkyl-OH, $-(C_0-C_4)$ -alkyl-O-(C_1-C_4)-alkyl or $-(C_1-C_3)$ -perfluoroalkyl;

R15 and R16 are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together with the carbon atom to which they are bonded form a 3- to 6 membered carbocyclic ring which is unsubstituted or substituted one to three times by R¹⁰ and

RI7 is $-(C_1-C_6)\text{-alkyl}$, $-(C_1-C_6)\text{-alkyl-OH}$, $-(C_1-C_6)\text{-alkyl-O-(C}_1\text{-C}_6\text{)-alkyl}$, $-(C_3-C_8)\text{-cycloalkyl}$, $-(C_1-C_6)\text{-alkyl-O-(C}_1\text{-C}_8\text{)-alkyl-(C}_3\text{-C}_8\text{)-cycloalkyl}$, $-(C_1-C_6)\text{-alkyl-(C}_3\text{-C}_8\text{)-cycloalkyl}$, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by $-\text{OH}$, $-\text{O-(C}_1\text{-C}_4\text{)-alkyl}$ or R^{10} ;

or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof.

2. (Currently amended) The compound according to claim 1, wherein

4,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyrido-oxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinoliny, tetrahydroquinolinyl, 1,4,5,6-tetrahydro pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl or xanthenyl, each of which wherein the thienyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

the substructure D is azetidine, azetine, azocane, azocane-2-one, cyclobutyl, cyclooctane, cyclooctene, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolan, 1,3-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, [1,4]oxazocane, [1,3]oxazocan-2-one, oxetan, oxocane, oxocan-2-one, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrrolidine, 5,6,7,8-tetrahydro-1H-azocin-2-one, tetrahydrofuran, tetrahydropyran, tetrahydropyridine, tetrazine, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thietan, thiocane, thiocane-1,1-dioxide, thiocane-1-oxide, thiocan-2-one, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, and is unsubstituted or substituted 1, 2, 3, 4, 5 or 6 times by R3, or is substituted 1 or 2 times by =O;

R¹ as a monocyclic or bicyclic 6- to 14-membered aryl is phenyl, naphthyl, biphenyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R8, or

-(C₀-C₃)-alkylene-het, then het is azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole,

1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, 1,2-oxepane, 1,2-oxathiolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrrolidine, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R^1 and R^3 with the atoms to which they are bonded form azocane, azocane-2-one, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazine, [1,4]dioxocane, dioxole, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, [oxocane, oxocan-2-one, piperazine, piperidine, pyran, pyrazine, pyridazine, pyrimidine or 5,6,7,8-tetrahydro-1H-azocin-2-one, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R^1 -N(R^2)-V form azepine, azetidine, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrrolidine, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

V is 2) phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R14, or
3) acridinyl, 8-aza-bicyclo[3.2.1]oct-3-yl, azaindole (< 1H-pyrrolopyridine), azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 1,4-diazepane, 4,5-dihydrooxazoliny, dioxazolyl, dioxaziny, 1,3-dioxolany, 1,3-dioxolenyl, 6H-1,5,2-dithiaziny, dihydrofuro[2,3-b]tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 4H-indazolyl, indolinyl, indolizinyl,

indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxathiopyanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, exazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydrochinolinyl, 4,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thiophenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, or thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, 1,3-thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, each of which is mono-, di- or trisubstituted independently of one another by R14;

M is

- 1) hydrogen;
- 2) (C₄-C₈) alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;
- 3) C(O)N(R11)R12;
- 4) (CH₂)_mNR⁴⁰,
- 5) (C₆-C₁₄) aryl, wherein the aryl is as defined above and wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;
- 6) (C₄-C₁₅) heterocyclyl, wherein the heterocyclyl is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
- 7) (C₃-C₈) cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R3 as 25) is -(C₀-C₃)-alkylene-O-CH₂-(C₁-C₃)-perfluoroalkylene-CH₂-O-(C₀-C₃)-alkyl;

two OR19 residues and adjacent atoms through which they are attached may form together a 1,3-dioxole ring or a 2,3-dihydro-[1,4]dioxine ring, each of which is substituted one, two, three or four times by R13;

R14 and R12 together with the nitrogen atom to which they are bonded may form azepine, azetidine, dioxazine, dioxazine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinene, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

R15 and R16 are independently of one another hydrogen, or -(C₁-C₆)-alkyl, or together with the carbon atom to which they are bonded form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R¹⁰; and

R17 is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₉-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by -OH, -O-(C₁-C₄)-alkyl or R¹⁰,

or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof.

3. (Currently amended) The compound according to claim 1, wherein

R⁰ as 1) is phenyl, naphthyl, biphenyl, anthryl or fluorenyl, each of which is mono-, di- or trisubstituted independently of one another by R8, or
3) is azabenzimidazolyl, benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, chromanyl, cinnolinyl, 2-furyl, 3-furyl, imidazolyl, indolyl, indazolyl, iso chromanyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, quinolinyl, quinazolinyl, quinoxalinyl, tetrazolyl, thiazolyl, 2-thienyl or 3-thienyl,
each of which is additionally substituted by acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, azidinyl, benzimidazolyl, benzofuranyl, benzothiophuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxazolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-

dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinoliny (benzimidazolyl), isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinoliny, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthroline, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyrido-oxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinoliny, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thietyl, thietyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietyl, thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,3-triazolyl, 1,2,3-triazoly, 1,2,4-triazolyl, 1,2,5-triazolyl, 4,3,4-triazolyl and xanthenyl, each of which wherein the thietyl is unsubstituted or mono-, di- or tri-substituted independently of one another by R8;

R8 as 1) is fluorine, chlorine or bromine,

provided R8 is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue;

substructure D is pyridyl, pyridyl N-oxide, pyridyl, pyrrolyl, furyl, thietyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl, or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by =O;

Q is a direct bond, -(C₀-C₂)-alkylene-C(O)-NR¹⁰-, -NR¹⁰-C(O)-NR¹⁰-, -NR¹⁰.C(O)-, -SO₂- or -(C₁-C₆)-alkylene;

R¹ is hydrogen, -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or substituted one to three times by R13, -(C₁-C₃)-alkylene-C(O)-NH-R⁰, -(C₁-C₃)-alkylene-C(O)-O-R15,

-(C₁-C₃)-perfluoroalkylene, -(C₁-C₃)-alkylene-S(O)-(C₁-C₄)-alkyl,
-(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl, -(C₁-C₃)-alkylene-S(O)₂-N(R⁴)-R⁵,
-(C₁-C₃)-alkylene-O-(C₁-C₄)-alkyl, or -(C₀-C₃)-alkylene-(C₃-C₈)-cycloalkyl, or
-(C₀-C₃)-alkylene-het, wherein the het is azepine, azetidine, aziridine, azirine, 1,4-diazepane,
4,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine,
dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine,
isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline,
ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine,
1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran,
pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole,
pyrrolidine, pyrrolidinone, pyrrolidine, tetrahydropyridine, tetrazine, tetrazole, thiadiazine
thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine,
thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine,
1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or
trisubstituted independently of one another by R14, or

R¹.N(R²).V-form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrrolidine, tetrahydropyridine, tetrazine, tetrazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

V is 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
3) -azaindole (1H-pyrrolopyridine), azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrrolidine, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, or thiazole, thiazolidine,

thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;


M is


- 1) hydrogen,
- 2) -(C₁-C₈)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
- 3) -C(O)-N(R11)-R12,
- 4) -(CH₂)_m-NR¹⁰,
- 5) phenyl or naphthyl, wherein the phenyl or naphthyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
- 6) azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, oxazole, {1,4} oxazepane, piperazine, piperazinone, piperidine, piperidinone, pyrazine, pyridazine, pyridazinone, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, tetrazine, tetrazole, thiadiazole, or thiazole, thiophene, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
- 7) -(C₃-C₈)-cycloalkyl, wherein the cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R3 is

- 1) hydrogen,
- 2) halogen,
- 3) -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 4) -(C₁-C₃)-perfluoroalkyl,
- 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 6) -(C₀-C₄)-alkylene-O-R19,
- 8) -CN,
- 9) -SO_s-R¹¹, wherein s is 1 or 2,
- 10) -SO_t-N(R¹¹)-R¹², wherein t is 1 or 2,
- 11) -(C₀-C₄)-alkylene-C(O)-R¹¹,

- 12) $-(C_0-C_4)\text{-alkylene-C(O)-O-R}^{11}$,
- 13) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-R}^{12}$,
- 14) $-(C_0-C_4)\text{-alkylene-N(R}^{11}\text{)-R}^{12}$,
- 15) $\text{NR}^{10}\text{-SO}_2\text{-R}^{10}$,
- 17) $-(C_0-C_2)\text{-alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-(C}_1\text{-C}_4\text{)-alkyl}$,
- 18) $-\text{C(O)-O-C(R15, R16)-O-C(O)-R17}$,
- 19) $-(C_0-C_2)\text{-alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-O-(C}_1\text{-C}_6\text{)-alkyl}$,
- 20) $-\text{C(O)-O-C(R15, R16)-O-C(O)-O-R17}$,
- 21) $-(C_0-C_4)\text{-alkylene-(C}_6\text{-C}_{14}\text{)-aryl}$, wherein aryl is as defined above and is mono-, di- or trisubstituted independently of one another by R13,
- 22) $-(C_0-C_4)\text{-alkylene-(C}_4\text{-C}_{15}\text{)-heterocyclyl}$, wherein the heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 23) $-(C_0-C_4)\text{-alkylene-(C}_3\text{-C}_8\text{)-cycloalkyl}$, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 24) $-(C_0-C_4)\text{-alkylene-het}$, wherein the het is as defined above and is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 25) $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$,
 $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-CF}_2\text{-CF}_2\text{-CH}_2\text{-O-(C}_0\text{-C}_3\text{)-alkyl}$, or
 $-(C_0-C_3)\text{-alkylene-O-CH}_2\text{-(C}_1\text{-C}_3\text{)-perfluoroalkylene-CH}_2\text{-OH}$,
- 26) $\text{SO}_w\text{-N(R}^{11}\text{)-R}^{13}$, wherein w is 1 or 2,
- 27) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-R}^{13}$,
- 28) $-(C_0-C_4)\text{-alkylene-N(R}^{11}\text{)-R}^{13}$, or
- 29) a residue selected from the group consisting of





wherein Me is methyl, and two OR19 residues and adjacent atoms through which they are attached form together with the atoms which they are attached to a 1,3-dioxole ring or a 2,3-dihydro-1,4-dioxine ring, which is substituted one, two, three or four times by R13;


R11 and R12 are independently of one another identical or different and are

- 1) hydrogen,
- 2) -(C₁-C₆)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 35) -(C₀-C₆)-alkyl-(C₆-C₁₄)-aryl, wherein the alkyl and aryl are independently from one another unsubstituted or mono-, di- or trisubstituted by R13, or
- [[4]]7) -O-R¹⁷, or
- 5) -(C₀-C₆)-alkyl-(C₄-C₁₅)-heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrrolidine, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

R13 is fluorine, chlorine, bromine, iodine, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -N(R¹⁰)-S(O)₂-R¹⁰, -S-R¹⁰, -SO₂-R¹⁰, -S(O)₂-N(R¹⁰)-R²⁰, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenoxy-, -O-CF₃, -(C₁-C₃)-perfluoroalkyl,

-(C₀-C₄)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-R17, -(C₁-C₄)-alkoxy-phenyl, -(C₀-C₄)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-O-R17, -O-R15, -NH-C(O)-NH-R¹⁰, -NH-C(O)-O-R¹⁰, or a residue selected from the group consisting of



wherein Me is methyl;

R15 and R16 are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R₁₀, and

R17 is $-(C_1-C_6)\text{-alkyl}$, $-(C_1-C_6)\text{-alkyl-OH}$, $-(C_1-C_6)\text{-alkyl-O-(C}_1\text{-C}_6\text{)-alkyl}$,
 $-(C_1-C_6)\text{-alkyl-O-(C}_1\text{-C}_8\text{)-alkyl-(C}_3\text{-C}_8\text{)-cycloalkyl}$, $-(C_1-C_6)\text{-alkyl-(C}_3\text{-C}_8\text{)-cycloalkyl}$,
wherein the cycloalkyl is unsubstituted or substituted one, two or three times by $-\text{OH}$,
 $-\text{O-(C}_1\text{-C}_4\text{)-alkyl}$ or R^{10} ,
or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof.

4. (Currently amended) The compound according claim 1, wherein

R0 as 1) is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or

3) is pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl,

thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl or pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,

and in addition is substituted by pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl, thieryl, 2-thienyl, or 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl or pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

R8 is 1) F, Cl, Br or I,
4) -C(O)-NH₂,
9) -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or methoxy, or
10) -O-(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or methoxy,
provided that R8 is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl;

substructure D is pyridyl, pyridyl-N-oxide, pyrrolyl, furyl, thieryl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl, or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by =O;

Q is a direct bond, -C(O)-, -SO₂- or -(C₁-C₆)-alkylene, -(C₀-C₂)-alkylene-C(O)-NR¹⁰-;

R¹ is hydrogen, -(C₁-C₂)-alkyl, -(C₁-C₃)-alkylene-C(O)-NH- R⁹, -(C₁-C₃)-perfluoroalkylene, -(C₁-C₃)-alkylene-C(O)-O-R¹⁵, -(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl or -(C₁-C₃)-alkylene-S(O)₂-N(R⁴)-R⁵, wherein R⁴ and R⁵ independently of one another are hydrogen atom or -(C₁-C₄)-alkyl,

R² is a direct bond or -(C₁-C₂)-alkylene, or

R⁴-N-R²-V form azetidine, azetidinone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, 1,4-oxazepane, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine,

thiazole, isothiazole, thiadiazole or thiomorpholine, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R14 is fluorine, chlorine, -OH, =O, -(C₁-C₈)-alkyl, -C(O)-OH, -CN, -NH₂, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-N[(C₁-C₈)-alkyl]₂, -C(O)-NH₂ or -N(R¹⁸)-R²¹, wherein R¹⁸ and R²¹ are independently from each other hydrogen, -(C₁-C₃)-perfluoroalkyl or -(C₁-C₄)-alkyl;

V is 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
3) ~~azaindole (1H-pyrrolopyridine), aziridine, azirine, azetidine, azetidinone, 1,4-diazepane, pyrrole, pyrrolidine, pyridonyl, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyrimidine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, tetrazine, tetrazole, azepine, diazirine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, pyridazine, piperidine, piperazine, pyrrolidinone, ketopiperazine, furan, pyran, dioxole, 1,4-oxazepane, oxazole, isoxazole, 2-isoxazoline, isoxazolidine, morpholine, oxirane, oxaziridine, 1,3-dioxolene, 1,3-dioxolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxaziridine, thiophene, thiopyran, thietan, thiazole, or isothiazole, isothiazoline, isothiazolidine, 1,2-oxathiolan, thiediazole, thiopyran, 1,2-thiazine, 1,3-thiazole, 1,3-thiazine, 1,4-thiazine, thiadiazine or thiomorpholine, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;~~

G is a direct bond, -(CH₂)_m, or -(CH₂)_m-NR¹⁰-;

m is zero, 1, 2, 3 or 4;


M is 1) hydrogen,
2) -(C₁-C₆)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
3) -C(O)-N(R¹¹)-R¹², or
6) heterocyclyl, wherein the heterocyclyl is selected from the group consisting of azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, oxazole, 1,4-oxazepane, piperazine, piperazinone, piperidine, piperidinone, pyrazine, pyridazine, pyridazinone, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, tetrazine, tetrazole, thiadiazole, or thiazole, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-

triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

7) (C₃-C₆)-cycloalkyl;

R3 is

- 1) hydrogen,
- 2) halogen,
- 3) -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 4) -(C₁-C₃)-perfluoroalkyl,
- 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 6) -(C₀-C₄)-alkylene-O-R19,
- 8) -CN,
- 8) -NR¹⁰-SO₂-R¹⁰,
- 9) -SO_s-R¹¹, wherein s is 1 or 2,
- 10) -SO_t-N(R¹¹)-R¹², wherein t is 1 or 2,
- 11) -(C₀-C₄)-alkylene-C(O)-R¹¹,
- 12) -(C₀-C₄)-alkylene-C(O)-O-R¹¹,
- 13) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-R¹²,
- 14) -(C₀-C₄)-alkylene-N(R¹¹)-R¹²,
- 17) -(C₀-C₂)-alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-(C₁-C₄)-alkyl,
- 18) -C(O)-O-C(R15, R16)-O-C(O)-R17,
- 19) -(C₀-C₂)-alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-O-(C₁-C₆)-alkyl,
- 20) -C(O)-O-C(R15, R16)-O-C(O)-O-R17,
- 25) -(C₀-C₃)-alkylene-O-CH₂-CF₂-CH₂-O-(C₀-C₃)-alkyl,
-(C₀-C₃)-alkylene-O-CH₂-CF₂-CF₂-CH₂-O-(C₀-C₃)-alkyl, or
-(C₀-C₃)-alkylene-O-CH₂-(C₁-C₃)-perfluoroalkylene-CH₂-OH,
- 26) -SO_w-N(R¹¹)-R¹³, wherein w is 1 or 2,
- 27) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-R¹³,
- 28) -(C₀-C₄)-alkylene-N(R¹¹)-R¹³, or
- 29) a residue selected from the group consisting of




wherein Me is methyl;

two OR19 residues and adjacent atoms through which they are attached may form together a 1,3-dioxole ring or a 2,3-dihydro-1,4-dioxine ring, each of which is substituted one, two, three or four times by R13;

R¹¹ and R¹² together with the nitrogen atom to which they are bonded form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrrolidine, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiadiazolidine, thiadiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or tri-substituted independently of one another by R13;

R13 is fluorine, chlorine, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -N(R¹⁰)-S(O)₂-R¹⁰, -S-R¹⁰, -SO₂-R¹⁰, -S(O)₂-N(R¹⁰)-R²⁰, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenoxy-, -O-CF₃, -(C₁-C₃)-perfluoroalkyl, -NH-C(O)-NH-R¹⁰, -(C₀-C₄)-alkyl-C(O)-O-C(R₁₅, R₁₆)-O-C(O)-R₁₇, -(C₁-C₄)-alkoxy-phenyl, -(C₀-C₄)-alkyl-C(O)-O-C(R₁₅, R₁₆)-O-C(O)-O-R₁₇, -O-R₁₅, -NH-C(O)-O-R¹⁰, or a residue selected from the group consisting of



wherein Me is methyl;

R15 and R16 are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R¹⁰; and

R17 is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₁-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by -OH, -O-(C₁-C₄)-alkyl or R¹⁰,

or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof.

5. (Currently amended) The compound according to claim 1, wherein

R0 is 1) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,

2) ~~indolyl, isoindolyl, benzofuranyl, benzothiophenyl, 1,3-benzodioxolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, chromanyl, isochromanyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridyl, purinyl or pteridinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,~~

3) ~~pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl, thieryl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl or pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and in addition is substituted by pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl, thieryl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and~~

pyrazinyl, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

R8 is 1) F, Cl, Br, or I,
4) -C(O)-NH₂,
9) -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or methoxy, or
10) -O-(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or methoxy,
provided that R8 is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₄)-alkyl residue;

substructure D is pyridyl, pyridyl-N-oxide, pyrrolyl, furyl, thiényl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl, or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R³, or is substituted 1 or 2 times by =O;

Q is a direct bond, -C(O)-, -SO₂-, -(C₁-C₆)-alkylene or -(C₀-C₂)-alkylene-C(O)-NR¹⁰-;

R¹ is hydrogen or -(C₁-C₂)-alkyl,

R² is a direct bond or -(C₁-C₂)-alkylene, or

R⁴-N(R²)₂-N-form-piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R14 is fluorine, chlorine, =O, -(C₁-C₄)-alkyl or -NH₂;

V is 2) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
3) azaindolyl (1H-pyrrolopyridyl), azetidine, azepine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diazirine, 1,3-dioxolane, dioxazole, furan, imidazole, isoquinoline, isothiazole, isothiazolidine, isothiazoline, isoxazole, 2-isoxazoline, isoxazolidine, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole,

1,2-oxathiolan, piperidine, pyran, pyrazine, pyrazole, pyridazine, piperazine, pyridine, pyridone, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, quinazoline, quinoline, tetrazine, tetrazole, thiadiazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, or 1,3-thiazole, thietan, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;


G is a direct bond, $-(\text{CH}_2)_m-$, or $-(\text{CH}_2)_n-\text{NR}^{10}-$;

m is zero, 1, 2, 3 or 4;

M is 1) hydrogen,
2) $-(\text{C}_1\text{-C}_6)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
6) heterocyclyl, wherein the heterocyclyl is selected from the group consisting of 1,4-diazepane, ketomorpholine, thiophene, pyridazine, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, pyridonyl, imidazole, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, or isothiazole, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, thiadiazole or thiomorpholine, each of which is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
7) $(\text{C}_3\text{-C}_6)$ -cycloalkyl;

R3 is 1) hydrogen,
2) halogen,
3) $-(\text{C}_1\text{-C}_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
4) $-(\text{C}_1\text{-C}_3)$ -perfluoroalkyl,
5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
6) $-(\text{C}_0\text{-C}_4)$ -alkylene-O-R19,
8) -CN,
9) $-\text{SO}_s-\text{R}^{11}$, wherein s is 1 or 2,
10) $-\text{SO}_t-\text{N}(\text{R}^{11})-\text{R}^{12}$, wherein t is 1 or 2,
11) $-(\text{C}_0\text{-C}_4)$ -alkylene-C(O)-R¹¹,

- 12) $-(C_0-C_4)\text{-alkylene-C(O)-O-R}^{11}$,
- 13) $-(C_0-C_4)\text{-alkylene-C(O)-N(R}^{11}\text{)-R}^{12}$,
- 14) $-(C_0-C_4)\text{-alkylene-N(R}^{11}\text{)-R}^{12}$,
- 15) $-\text{NR}^{10}\text{SO}_2\text{R}^{10}$,
- 17) $-(C_0-C_2)\text{alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-(C}_1\text{-C}_4\text{)-alkyl}$,
- 18) $-\text{C(O)-O-C(R15, R16)-O-C(O)-R17}$,
- 19) $-(C_0-C_2)\text{alkylene-C(O)-O-(C}_2\text{-C}_4\text{)-alkylene-O-C(O)-O-(C}_1\text{-C}_6\text{)-alkyl}$,
- 20) $-\text{C(O)-O-C(R15, R16)-O-C(O)-O-R17}$, or
- 29) a residue selected from the group consisting of



wherein Me is methyl;

R19 is a) hydrogen,
b) -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
c) -CF₃, or
d) -CHF₂;


R11 and R12 are independently of one another identical or different and are

- 1) hydrogen,
- 2) -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) -(C₀-C₆)-alkyl-(C₃-C₆)-cycloalkyl, or
- 7) -O-R¹⁷, or

8) ~~—(C₀-C₆)-alkyl-(C₄-C_{4.5})-heterocyclyl~~, wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or tri-substituted by R¹³ and wherein the heterocyclyl is azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine, or

~~R¹¹ and R¹² together with the nitrogen atom to which they are bonded form azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine;~~

R¹³ is fluorine, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₃-C₆)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -S-R¹⁰, -SO₂-R¹⁰, -(C₁-C₃)-perfluoroalkyl, or a residue selected from the group consisting of



wherein Me is methyl;

R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₄)-alkyl or -(C₁-C₃)-perfluoroalkyl;

R¹⁵ and R¹⁶ are independently of one another hydrogen, -(C₁-C₄)-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R¹⁰, and

R¹⁷ is -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-OH, -(C₁-C₆)-alkyl-O-(C₁-C₆)-alkyl, -(C₁-C₆)-alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, -(C₀-C₆)-alkyl-(C₃-C₈)-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by -OH, -O-(C₁-C₄)-alkyl or R¹⁰,

or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof.

6. (Currently amended) The compound according to claim 1, wherein

R0 is 1) phenyl, wherein the phenyl is unsubstituted or mono- or disubstituted independently of one another by R8,
2) pyridyl or benzothiophenyl, wherein the pyridyl and benzothiophenyl are is unsubstituted or mono- or disubstituted independently of one another by R8, or
3) thiaryl, thiadiazolyl, isoxazolyl or thiazolyl, each of which is substituted by thiaryl, 2-thienyl or 3-thienyl, wherein the thiaryl, 2-thienyl or 3-thienyl is unsubstituted or mono- or disubstituted independently of one another by R8;

R8 is F, Cl, Br, -OCH₃ or -C(O)-NH₂;

substructure D is pyridyl, pyridyl-N-oxide, pyrrolyl, thiaryl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrimidinyl, pyridazinyl or pyrazinyl, and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by =O;

Q is a direct bond, -C(O)-, -SO₂-, -CH₂-C(O)-NH-, methylene or ethylene;

R¹ is hydrogen,

;

R² is a direct bond or methylene, or

~~R⁴-N(R²)₂-V~~ form azetidine, pyrrolidine, piperidine and piperazine;

R14 is fluorine, chlorine, =O, methyl, ethyl or -NH₂;

V is 2) phenyl, wherein the phenyl is unsubstituted or mono- or disubstituted independently of one another by R14, or
3) azaindolyl (1H-pyrrolopyridyl), azetidine, 1,4-diazepane, isoxazole, isocoumarine, piperazine, piperidine, pyrazine, pyridazine, pyrimidine, or pyrrolidine, quinazoline, quinoline or tetrahydropyran, each of which is unsubstituted or mono- or disubstituted independently of one another by R14;

G is a direct bond, -(CH₂)_m, or -(CH₂)_m-NR¹⁰-;

m is zero, 1 or 2;

M is

- 1) hydrogen,
- 2) (C_2-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- or disubstituted independently of one another by R14, or
- 6) azepanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, ketomorpholinyl, morpholinyl, [1,4]Oxazepanyl, piperidinyl, piperidonyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, or pyrrolidinyl, 4,4,5,6-tetrahydro-pyridazinyl, or tetrahydropyranyl, each of which is unsubstituted or mono- or disubstituted independently of one another by R14, or
- 7) cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is unsubstituted or mono- or disubstituted independently of one another by R14;

R3 is

- 1) hydrogen,
- 2) F or Cl,
- 3) $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 4) $-(C_1-C_3)$ -perfluoroalkyl,
- 5) phenyl, wherein the phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 6) $-(C_0-C_2)$ -alkylene-O-R19,
- 8) -CN,
- 9) $-SO_8-R^{11}$, wherein s is 1 or 2,
- 10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,
- 11) $-(C_0-C_4)$ -alkylene-C(O)-R¹¹,
- 12) $-(C_0-C_4)$ -alkylene-C(O)-O-R¹¹,
- 13) $-(C_0-C_4)$ -alkylene-C(O)-N(R¹¹)-R¹²,
- 14) $-(C_0-C_4)$ -alkylene-N(R¹¹)-R¹²,
- 15) $-NR^{10}-SO_2-R^{10}$,
- 17) $-(C_0-C_2)$ alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-(C₁-C₄)-alkyl,
- 18) -C(O)-O-C(R15, R16)-O-C(O)-R17,
- 19) $-(C_0-C_2)$ alkylene-C(O)-O-(C₂-C₄)-alkylene-O-C(O)-O-(C₁-C₆)-alkyl or
- 20) -C(O)-O- C(R15, R16)-O-C(O)-O-R17;

R19 is a) hydrogen,

- b) $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
- c) $-CF_3$, or
- d) $-CHF_2$;

R11 and R12 are independently of one another identical or different and are

- 1) hydrogen,
- 2) $-(C_1-C_4)$ -alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)$ -alkyl- (C_3-C_6) -cycloalkyl, or
- 7) $-O-R^{17}$, or
- 8) $-(C_0-C_6)$ -alkyl-heterocyclyl, wherein the alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein the heterocyclyl is azetidine, imidazolidine, morpholine, (1,4)-oxazepane or pyrrolidine, or

R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, imidazolidine, morpholine, (1,4)-oxazepane, piperazine, piperidine, pyrrolidine or thiomorpholine;

R13 is fluorine, $-CN$, $=O$, $-OH$, $-CF_3$, $-C(O)-O-R^{10}$, $-C(O)-N(R^{10})-R^{20}$, $-N(R^{10})-R^{20}$, $-(C_3-C_6)$ -cycloalkyl, $-(C_0-C_3)$ -alkylene-O-R¹⁰, $-Si-(CH_3)_3$, $-S-R^{10}$, $-SO_2-R^{10}$, or $-(C_1-C_3)$ -perfluoroalkyl;

R¹⁰ and R²⁰ are independently of one another hydrogen, $-(C_1-C_4)$ -alkyl or $-(C_1-C_3)$ -perfluoroalkyl;

R¹⁵ and R¹⁶ are independently of one another hydrogen, $-(C_1-C_4)$ -alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R¹⁰, and

R¹⁷ is $-(C_1-C_6)$ -alkyl, $-(C_1-C_6)$ -alkyl-OH, $-(C_1-C_6)$ -alkyl-O-(C₁-C₆)-alkyl, $-(C_1-C_6)$ -alkyl-O-(C₁-C₈)-alkyl-(C₃-C₈)-cycloalkyl, $-(C_0-C_6)$ -alkyl-(C₃-C₈)-cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted one, two or three times by $-OH$, $-O-(C_1-C_4)$ -alkyl or R¹⁰, or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof.

7. (Currently amended) The compound according to claim 1, wherein

R0 is 42) pyridyl or benzothiophenyl, wherein the pyridyl and benzothiophenyl are ~~is~~ unsubstituted or mono- or disubstituted independently of one another by R8, or
23) thienyl, thiadiazolyl, isoxazolyl and thiazolyl, each of which is substituted by thienyl, 2-thienyl and 3-thienyl, wherein the thienyl, 2-thienyl or 3-thienyl is unsubstituted or mono- or disubstituted independently of one another by R8;

R8 is F, Cl, Br, -OCH₃ or -C(O)-NH₂;

substructure D is pyridyl and is unsubstituted or substituted 1, 2, 3 or 4 times by R3, or is substituted 1 or 2 times by =O;

Q is -CH₂-C(O)-NH- or methylene;

R¹ is hydrogen atom;

R² is a direct bond;

R14 is fluorine, chlorine, =O, methyl, ethyl or -NH₂;

V is piperidine, wherein the piperidine is unsubstituted or mono- or disubstituted independently of one another by R14;

G is a direct bond;

M is hydrogen, (C₂-C₄)-alkyl, or pyridyl, wherein the alkyl or pyridyl is unsubstituted or mono- or disubstituted independently of one another by R14;

R3 is 1) hydrogen,
2) fluorine, or chlorine,
3) -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
6) -(C₀-C₂)-alkylene-O-R19,
12) -(C₀-C₄)-alkylene-C(O)-O-R¹¹ or
13) -(C₀-C₄)-alkylene-C(O)-N(R¹¹)-R¹²;

R19 is

- a) hydrogen, or
- b) -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

R11 and R12 are independently of one another identical or different and are

- 1) hydrogen, or
- 2) -(C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded form a:azetidine, imidazolidine, morpholine, (1,4)-oxazepane, piperazine, piperidine, pyrrolidine or thiomorpholine;

R13 is fluorine, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, or -(C₀-C₃)-alkylene-O-R¹⁰, and


R¹⁰ and R²⁰ are independently of one another hydrogen, -(C₁-C₄)-alkyl or -(C₁-C₃)-perfluoroalkyl, or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof.

8. (Currently amended) The compound according to claim 1, wherein the compound is

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid methyl ester,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2,5-dicarboxylic acid 5-amide 2-[(1-isopropyl-piperidin-4-yl)-amide],
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[3,2-b]pyridine-2- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid ,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylcarbamoyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid methyl ester,

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylcarbamoyl)-1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid ,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(2-hydroxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide ,
1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-(2-hydroxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
1-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-(2-methoxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide or
1-(6-Chloro-benzo[b]thiophen-2-ylmethyl)-5-(2-hydroxy-ethoxy)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide,
or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof.

9. (Withdrawn) A process for the preparation of a compound according to claim 1, which comprises condensing a compound of formula **29** with a compound of the formula $HR^{8'}$ to give a compound of formula **30** and converting the compound of the formula **30** into a compound of the formula I,



wherein the residue $R^{8'}$ has the donation of $-N(R^1)-R^2-V-G-M$ as indicated claim 1, but where in $R^{8'}$ functional groups can also be present in the form of groups that are subsequently transformed into the final functional groups present in $-N(R^1)-R^2-V-G-M$, and where the residue R^{54} denotes the group $-Q-R^0$ or can denote a group which is subsequently transformed into the group $-Q-R^0$, and where the group $-C(O)-R^{53}$ can be a carboxylic acid group or derivatives thereof, and where the groups R^{3a} in the formulae **29** and **30** have the corresponding definitions of R^3 in formula I as defined in claim 1 or functional groups in them can also be present in protected form or in the form of precursor groups.

10. (Currently amended) A pharmaceutical composition, comprising at least one compound according to claim 1, or a stereoisomer or a mixture of stereoisomers thereof in any ratio, or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. (Withdrawn) A method for inhibiting factor Xa in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.

12. (Withdrawn) A method for inhibiting factor VIIa in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.

13. (Withdrawn) A method for influencing blood coagulation in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.

14. (Withdrawn) A method for inhibiting influencing blood fibrinolysis in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.

15. (Withdrawn) A method for treating abnormal thrombus formation, acute myocardial infarction, cardiovascular disorders, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication, bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post coronary or venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee or hip surgery, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulopathy occurring in vascular systems during septic shock, viral infections or cancer, or reducing an inflammatory response, fibrinolysis, or treatment of coronary heart disease, myocardial infarction, angina pectoris, vascular restenosis, for example restenosis following angioplasty like PTCA, adult respiratory distress syndrome, multi-organ failure and disseminated intravascular clotting disorder, deep vein or proximal vein thrombosis, which can occur following surgery, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound according to claim 1.